Status:
COMPLETED
Study to Compare Different Formulations of AZD3355
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to compare different formulations of AZD3355 in regard to possible adverse events such as sensations of numbness, tinglings and heat in the skin.
Eligibility Criteria
Inclusion
- Provision of written informed consent
- Female subjects with no childbearing potentials or using highly efficient contraceptive methods
- Clinically normal physical findings
Exclusion
- Clinically significant illness within 2 weeks prior to the first dose of investigational product
- History of clinically significant disease
- Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2008
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00688402
Start Date
April 1 2008
End Date
June 1 2008
Last Update
December 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Varvsgatan, Lulea, Sweden